Drug Research

Despite their track record of demonstrating significant therapeutic efficacy, biologics still face daunting challenges in their drug delivery. Biologics such as monoclonal antibodies (mAbs) and some vaccines are largely administered via injection or by infusion. These methods can often...

The pharmaceutical sector is still a hub for new patent developments. The development of novel treatment paradigms, the severity of unfulfilled requirements, and the increasing significance of technology like pharmacogenomics, digital therapies, and artificial intelligence are what propel activity....

The creation of a tool that can enable organic chemical processes that were not possible before has given the pharmaceutical business new ways to make effective drugs more quickly. In the past, most drugs were put together using alkyl building...

Quick delivery of toxicological materials According to Alejandro Fernandez Martell and James Berrie from Lonza, a bottleneck has developed in the supply of toxicological data to support INDs for novel therapies and, therefore, delivery of FIH studies, as a result...

ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, and Sitero LLC, a next-generation clinical trial solutions provider, today announced an expansion of their strategic partnership. This collaboration integrates Sitero's unified eClinical technology platform...

The radiopharmaceutical industry is growing very quickly. In the past few years, there have been more mergers and acquisitions (M&A) and partnerships. Investors can find good business chances by learning more about this field. Recent mergers, purchases, and joint deals...

The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion agreement last year. The pharma firm said that GSK5764227 (GSK'227, formerly known as HS-20093) has been granted the...